54P Targeted treatment options for childhood hepatoblastoma using high-throughput drug screening

Hepatoblastoma (HB) is a pediatric malignancy with prevalence of 1:1 000 000 in Europe. Median age at diagnosis is one year. Current treatment entails chemotherapy (platinum-based alone or combined with doxorubicin) followed by surgery (tumor resection or liver transplantation). Survival rate of HB patients has improved; however, high-risk HB tumors are still difficult to treat with 20-30% of HB patients responding poorly to current treatment modalities. Furthermore, while current treatment modalities improve the prognosis, side effects of the chemotherapeutics have a significant effect on the life quality of HB survivors.